GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (NAS:ARGX) » Definitions » Capex-to-Revenue

argenx SE (argenx SE) Capex-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is argenx SE Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

argenx SE's Capital Expenditure for the three months ended in Dec. 2023 was $0.00 Mil. Its Revenue for the three months ended in Dec. 2023 was $406.84 Mil.

Hence, argenx SE's Capex-to-Revenue for the three months ended in Dec. 2023 was 0.00.


argenx SE Capex-to-Revenue Historical Data

The historical data trend for argenx SE's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Capex-to-Revenue Chart

argenx SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.60 0.13 0.24 0.25 0.04

argenx SE Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of argenx SE's Capex-to-Revenue

For the Biotechnology subindustry, argenx SE's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


argenx SE's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, argenx SE's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where argenx SE's Capex-to-Revenue falls into.



argenx SE Capex-to-Revenue Calculation

argenx SE's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-43.812) / 1226.316
=0.04

argenx SE's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 406.837
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


argenx SE  (NAS:ARGX) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


argenx SE Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of argenx SE's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


argenx SE (argenx SE) Business Description

Address
Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.